These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 23066316)

  • 21. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.
    Sandborn WJ; Rutgeerts P; Enns R; Hanauer SB; Colombel JF; Panaccione R; D'Haens G; Li J; Rosenfeld MR; Kent JD; Pollack PF
    Ann Intern Med; 2007 Jun; 146(12):829-38. PubMed ID: 17470824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy.
    Lichtiger S; Binion DG; Wolf DC; Present DH; Bensimon AG; Wu E; Yu AP; Cardoso AT; Chao J; Mulani PM; Lomax KG; Kent JD
    Aliment Pharmacol Ther; 2010 Nov; 32(10):1228-39. PubMed ID: 20955442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of infliximab retreatment after consecutive discontinuation of infliximab and adalimumab in refractory Crohn's disease.
    Brandse JF; Peters CP; Gecse KB; Eshuis EJ; Jansen JM; Tuynman HA; Löwenberg M; Ponsioen CY; van den Brink GR; DʼHaens GR;
    Inflamm Bowel Dis; 2014 Feb; 20(2):251-8. PubMed ID: 24378599
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Similar response to adalimumab in patients with active Crohn's disease either naive to biologic agents or with prior loss of response or intolerance to infliximab.
    Triantafillidis JK; Mantzaris G; Karagiannis J; Papavasilliou E; Papatheodoridis G; Fouskas J; Malgarinos G; Gikas A; Papamichael K; Mathou N; Symboulakis E; Karamanolis D
    Rev Med Chir Soc Med Nat Iasi; 2010; 114(1):85-90. PubMed ID: 20509281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab.
    Ma C; Panaccione R; Heitman SJ; Devlin SM; Ghosh S; Kaplan GG
    Aliment Pharmacol Ther; 2009 Nov; 30(10):977-86. PubMed ID: 19681810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adalimumab for Crohn's disease in clinical practice at Mayo clinic: the first 118 patients.
    Swoger JM; Loftus EV; Tremaine WJ; Faubion WA; Pardi DS; Kane SV; Hanson KA; Harmsen WS; Zinsmeister AR; Sandborn WJ
    Inflamm Bowel Dis; 2010 Nov; 16(11):1912-21. PubMed ID: 20848486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of adalimumab in the management of refractory Crohn's disease.
    Ho GT; Smith L; Aitken S; Lee HM; Ting T; Fennell J; Lees CW; Palmer KR; Penman ID; Shand AG; Arnott ID; Satsangi J
    Aliment Pharmacol Ther; 2008 Feb; 27(4):308-15. PubMed ID: 18081730
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease.
    Loftus EV; Johnson SJ; Yu AP; Wu EQ; Chao J; Mulani PM
    Eur J Gastroenterol Hepatol; 2009 Nov; 21(11):1302-9. PubMed ID: 19465858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adalimumab for orbital myositis in a patient with Crohn's disease who discontinued infliximab: a case report and review of the literature.
    Verma S; Kroeker KI; Fedorak RN
    BMC Gastroenterol; 2013 Apr; 13():59. PubMed ID: 23556424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Adalimumab treatment in infliximab-resistant pediatric patient with Crohn's disease].
    Veres G; Putz R; Szabó D; Molnár K; Bodánszky H; Dezsofi A; Arató A
    Orv Hetil; 2009 Oct; 150(40):1858-60. PubMed ID: 19789146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients.
    Baert F; Glorieus E; Reenaers C; D'Haens G; Peeters H; Franchimont D; Dewit O; Caenepeel P; Louis E; Van Assche G;
    J Crohns Colitis; 2013 Mar; 7(2):154-60. PubMed ID: 22537637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.
    Yang E; Panaccione N; Whitmire N; Dulai PS; Vande Casteele N; Singh S; Boland BS; Collins A; Sandborn WJ; Panaccione R; Battat R
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1031-1038. PubMed ID: 32329532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of adalimumab for the Crohn's disease: a systematic review and meta-analysis of published randomized placebo-controlled trials.
    Song YN; Zheng P; Xiao JH; Lu ZJ
    Eur J Clin Pharmacol; 2014 Aug; 70(8):907-14. PubMed ID: 24880961
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland.
    Russo EA; Iacucci M; Lindsay JO; Campbell S; Hart A; Hamlin J; Orchard T; Arebi N; Nightingale J; Jacyna MR; Gabe SM; O'Connor M; Harris AW; O'Morain C; Ghosh S
    Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):334-9. PubMed ID: 19528808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naïve Patients.
    Aliyev ER; Hay JW; Hwang C
    Pharmacotherapy; 2019 Feb; 39(2):118-128. PubMed ID: 30565265
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease.
    Benmassaoud A; Al-Taweel T; Sasson MS; Moza D; Strohl M; Kopylov U; Paradis-Surprenant L; Almaimani M; Bitton A; Afif W; Lakatos PL; Bessissow T
    Dig Dis Sci; 2018 May; 63(5):1302-1310. PubMed ID: 29243105
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].
    Rozpondek P; Zwolińska-Wcisło M; Przybylska M; Mach T
    Przegl Lek; 2011; 68(9):602-5. PubMed ID: 22335009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is there a benefit from the concomitant use of immunosupression with anti-TNF in Crohn's disease; heads or tails?
    Lakatos PL
    Rev Recent Clin Trials; 2009 Sep; 4(3):152-8. PubMed ID: 20028325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's disease.
    Gagniere C; Beaugerie L; Pariente B; Seksik P; Amiot A; Abitbol V; Allez M; Cosnes J; Sokol H
    J Crohns Colitis; 2015 Apr; 9(4):349-55. PubMed ID: 25547977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adalimumab in patients with Crohn's disease--safety and efficacy in an open-label single centre study.
    Seiderer J; Brand S; Dambacher J; Pfennig S; Jürgens M; Göke B; Ochsenkühn T
    Aliment Pharmacol Ther; 2007 Apr; 25(7):787-96. PubMed ID: 17373917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.